A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

NCT02082210 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Hepatocellular Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer

Interventions

DRUG: Emibetuzumab
DRUG: Ramucirumab

Sponsor

Eli Lilly and Company